首页> 外文期刊>Surgical infections >Surgical Treatment for Primary Mycotic Aneurysms Using Endovascular Therapy, Focusing on Patient Selection: Single-Center Experience
【24h】

Surgical Treatment for Primary Mycotic Aneurysms Using Endovascular Therapy, Focusing on Patient Selection: Single-Center Experience

机译:使用血管内疗法的原发性毒性动脉瘤的手术治疗,重点关注患者选择:单中心体验

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Mycotic aneurysms (MAs) are relatively rare but life-threatening. Some recent reports have described the use of endovascular therapy for their treatment; however, this still is a controversial treatment, and a definite target population has not been determined.Methods: We performed surgery on 34 patients with MAs from March 2005 to March 2019. Twenty patients who underwent open surgery (OS) first comprised the OS group, and 14 patients who underwent endovascular therapy first comprised the stent-graft (SG) group. We analyzed between-group differences, long-term outcomes, and risk factors for death retrospectively. Patients in the OS group had a higher initial white blood cell count than those in the SG group (p = 0.047). The SG group had more patients with a low albumin concentration (≤2.0 mg/dL) than did the OS group (p = 0.026).Results: There were no significant differences in the operative mortality rates between the groups (p = 0.773). Additional procedures were required more often in the SG than the OS group (p = 0.0013). The overall survival rate as estimated by the Kaplan–Meier method was 88% at 1 month, 67% at 1 year, 57% at 3 years, and 45% at 10 years. In the univariable analysis, chronic obstructive pulmonary disease (COPD) was a risk factor for death (p = 0.003).Conclusions: Endovascular therapy for MAs produced reasonable outcomes when patient selection was based on the activity level, nutritional condition, and degree of inflammation. Endovascular therapy may become an option for patients with a low albumin concentration or COPD despite the fact that additional procedures may be needed.
机译:背景:毒性动脉瘤(MAS)相对罕见但危及生命。一些最近的报告描述了使用血管内治疗的治疗;然而,这仍然是一个有争议的治疗,并且尚未确定一个明确的目标群体。方法:我们在2005年3月至2019年3月的34名MAS患者进行了手术。二十次接受开放外科(OS)的患者首先由OS集团组成和14名接受血管内治疗的患者首先由支架 - 移植物(SG)组组成。我们回顾性地分析了组差异,长期结果和死亡危险因素。 OS组患者的初始白细胞计数高于SG组的初始白细胞计数(P = 0.047)。 SG组更高的白蛋白浓度(≤2.0mg/ d1)的患者比OS组(p = 0.026)。结果:组之间的手术死亡率没有显着差异(p = 0.773)。在SG中比OS组更常见的额外程序(P = 0.0013)。 Kaplan-Meier方法估计的整体存活率在1个月内为88%,1年为67%,3岁为57%,10年为45%。在不可明显的分析中,慢性阻塞性肺病(COPD)是死亡的危险因素(p = 0.003)。结论:当患者选择基于活动水平,营养状况和炎症程度时,MAS的血管内疗法产生合理的结果。尽管可能需要额外的程序,但血管内治疗可能成为低白蛋白浓度或COPD患者的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号